Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Horizon Therapeutics Public Trading Down 1.0 %
NASDAQ:HZNP traded down $0.64 during trading on Friday, hitting $60.57. 40,177 shares of the company's stock traded hands, compared to its average volume of 3,813,947. The stock has a fifty day moving average of $78.58 and a two-hundred day moving average of $91.94. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.05 and a quick ratio of 3.79. Horizon Therapeutics Public has a 12-month low of $60.44 and a 12-month high of $120.54. The firm has a market cap of $13.95 billion, a P/E ratio of 18.89, a PEG ratio of 1.54 and a beta of 1.12.
Horizon Therapeutics Public (NASDAQ:HZNP - Get Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.36 by ($0.29). Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. The business had revenue of $876.40 million for the quarter, compared to analysts' expectations of $938.82 million. During the same quarter in the previous year, the company earned $1.62 earnings per share. The business's quarterly revenue was up 5.3% on a year-over-year basis. As a group, sell-side analysts expect that Horizon Therapeutics Public will post 4.27 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the stock. Oppenheimer reaffirmed a "buy" rating and issued a $140.00 price target on shares of Horizon Therapeutics Public in a report on Friday, July 8th. TheStreet lowered shares of Horizon Therapeutics Public from a "b" rating to a "c+" rating in a research report on Tuesday. UBS Group lowered shares of Horizon Therapeutics Public from a "buy" rating to a "neutral" rating and reduced their price target for the company from $137.00 to $71.00 in a research report on Thursday, August 4th. Morgan Stanley reduced their price target on shares of Horizon Therapeutics Public from $135.00 to $90.00 and set an "overweight" rating for the company in a research report on Thursday, August 4th. Finally, BMO Capital Markets reduced their price target on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an "outperform" rating for the company in a research report on Thursday, August 4th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $117.22.
Insider Buying and Selling at Horizon Therapeutics Public
In other Horizon Therapeutics Public news, CEO Timothy P. Walbert sold 25,000 shares of the company's stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $92.34, for a total transaction of $2,308,500.00. Following the completion of the sale, the chief executive officer now directly owns 435,826 shares in the company, valued at $40,244,172.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, EVP Andy Pasternak sold 762 shares of the company's stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $85.36, for a total transaction of $65,044.32. Following the completion of the transaction, the executive vice president now directly owns 38,897 shares of the company's stock, valued at $3,320,247.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Timothy P. Walbert sold 25,000 shares of the company's stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $92.34, for a total transaction of $2,308,500.00. Following the transaction, the chief executive officer now directly owns 435,826 shares of the company's stock, valued at $40,244,172.84. The disclosure for this sale can be found here. Insiders sold a total of 55,784 shares of company stock worth $5,100,633 over the last three months. Company insiders own 2.50% of the company's stock.
